As Cannabis Markets Continue to Develop, Demand for Clinical Research Rises

New Jersey Law Journal (reprinted with permission)

9.6.2021

This New Jersey Law Journal article written by Wilentz Shareholder Lisa Gora and Cooper Levenson attorney Brittany Bonetti is an overview of the DEA’s recent actions to allow more cannabis cultivators to provide a broader cannabis supply for research, and the parameters under NJ law through which researchers can be at the forefront of cannabis research.

*Cannabis Law Disclaimer: Per federal law, under the Controlled Substances Act, marijuana is categorized as a Schedule I controlled substance.  Possession, use, distribution, and/or sale of cannabis is a Federal crime and is subject to related Federal policy, regardless of any state law that may authorize certain marijuana activity.  Compliance with state marijuana law does not equal compliance with federal law.  Legal advice provided by Wilentz, Goldman & Spitzer, P.A. is designed to counsel clients regarding the validity, scope, meaning, and application of existing and/or proposed cannabis law. Wilentz, Goldman & Spitzer, P.A. will not provide guidance or assistance in circumventing or violating Federal or state cannabis law or policy, and any advice provided by Wilentz, Goldman & Spitzer, P.A. should not be construed as such.